As it works to advance an HIV vaccine candidate, the University of Maryland’s Institute of Human Virology this week received a $14.4 million grant for its…

Following the June decision by a CDC committee to recommend against any use of AstraZeneca’s FluMist Quadrivalent for the upcoming flu season, a Canadian study…

Scientists have been developing vaccines that could stop disease outbreaks more quickly. Now, researchers at the Massachusetts Institute of Technology are…

Vaxart has been keeping busy with R&D for its oral vaccines, and now, the company is adding another project to its list. The South San Francisco-based…

On the heels of devastating Phase III trial results for its pancreatic cancer vaccine, NewLink Genetics will undergo a restructuring, downsizing by 100…

Vienna, Austria’s Hookipa Biotech is taking a cytomegalovirus vaccine candidate into first-in-human trials. Dubbed HB-101, the vaccine will undergo Phase I…

An HIV vaccine research team led by Texas Biomedical Research Institute has secured $23 million in NIH grant funding to explore an approach that will utilize…

On Monday, the New Jersey pharma announced its rVSV-ZEBOV has won the FDA’s Breakthrough Therapy Designation and the EMA’s Priority Medicines status.